The role of TCGA molecular classification in clear cell endometrial carcinoma

Article Oncology

Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature

Antonio Raffone et al.

Summary: LVSI has an independent prognostic value for patients with endometrial carcinoma, increasing the risk of death and recurrence.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Clear cell carcinoma of the endometrium

Giorgio Bogani et al.

Summary: Clear cell endometrial carcinoma is a rare and poorly understood cancer type. Genetic profiling can assess prognosis, with most patients characterized by p53 abnormality or NSMP type. Patients with POLE mutation have a good prognosis, while chemotherapy is effective for NSMP and p53 abnormal patients. MMRd patients may not benefit from chemotherapy, and immune checkpoint inhibitors may be more suitable for them. Further clinical trials are needed to clarify the treatment strategies for clear cell endometrial carcinoma.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O'Malley et al.

Summary: Pembrolizumab demonstrated durable antitumor activity and encouraging survival outcomes in previously treated patients with MSI-H/dMMR endometrial cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Obstetrics & Gynecology

HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma

Alain Cagaanan et al.

Summary: There is increasing evidence that the diagnosis and treatment of clear cell carcinoma (CCC) is challenging and has substantial overlap with other types of endometrial carcinoma. Evaluating different factors influencing the HER2 status can help determine the eligibility of patients for HER2-targeted therapy.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)

Add to Collection

Article Oncology

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Oaknin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Beyond Serous: Treatment Options for Rare Endometrial Cancers

Erin Crane

Summary: Rare endometrial cancers are aggressive malignancies that are often diagnosed at an advanced stage and have a higher mortality rate compared to common low-grade tumors. Standard treatment includes surgery, radiation, and chemotherapy, with the potential for incorporating immunotherapy in the future. The rarity of these cancers has hindered the development of effective therapies, but molecular profiling has provided potential targets for personalized treatment.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer

Mikko Loukovaara et al.

Summary: The study suggests that MMR protein and MLH1 methylation status can predict the response to adjuvant therapy in endometrial cancer. Whole pelvic radiotherapy and chemotherapy combined with radiotherapy were associated with improved disease-specific survival in certain subgroups, while they were associated with poor disease-specific survival in other subgroups.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Kimberly K. Leslie et al.

Summary: The study suggests that mutations in the TP53 gene are associated with improved progression-free survival (PFS) and overall survival (OS) in advanced endometrial cancer patients receiving bevacizumab, compared to temsirolimus. This indicates that TP53 mutational status may serve as a potential biomarker for guiding treatment choices in endometrial cancer patients.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis

Jessica N. McAlpine et al.

Summary: Endometrial cancers with pathogenic POLE mutations are not associated with traditional risk parameters, and patients do not seem to benefit from adjuvant therapy. Low rates of recurrence/progression and high salvage rates may allow for safely decreasing treatment intensity for these patients.

CANCER (2021)

Add to Collection

Review Oncology

Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis

Antonio Travaglino et al.

Summary: This study assessed the prognostic value of MMRd and p53wt groups in endometrial CCC, finding that MMRd CCCs have a favorable prognosis and may be managed together with MMRd endometrioid carcinoma, while p53wt CCCs appear to have a prognosis more similar to p53abn CCCs.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma

Antonio Raffone et al.

Summary: The study suggests that deep myometrial invasion is not an independent prognostic factor for overall survival in endometrial carcinoma patients, but appears to affect the risk of recurrence independently from the TCGA groups.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Review Oncology

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines

Angela Santoro et al.

Summary: Histopathological classification of endometrial carcinoma divides tumors into low-grade and high-grade groups, while TCGA identifies four molecular categories: POLE/ultramutated, microsatellite instability (MSI)/hypermutated, copy-number low/endometrioid, and copy-number high/serous-like. The classification based on tumor morphology and molecular features plays a crucial role in prognosis and guiding treatment strategies.

CANCERS (2021)

Add to Collection

Article Oncology

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis

Jessica N. McAlpine et al.

Summary: Patients with ECs harboring pathogenic POLE mutations do not benefit from adjuvant therapy, as these mutations are not associated with most traditional risk parameters, and they exhibit low rates of adverse events with high and sustained salvage rates in cases of recurrence.

CANCER (2021)

Add to Collection

Letter Cell Biology